SEC Comment Letter 0000000000-22-012720 to NKGen Biotech, Inc. (NKGN, NKGNW) (CIK 0001845459)
NKGen Biotech, Inc. (NKGN, NKGNW) (CIK 0001845459)
Date: Nov. 23, 2022 · CIK: 0001845459 · Accession: 0000000000-22-012720
AI Filing Summary & Sentiment
File numbers found in text: 001-40427
Letter
United States securities and exchange commission logo November 23, 2022 James A Graf Chief Executive Officer Graf Acquisition Corp. IV 1790 Hughes Landing Blvd., Suite 400 The Woodlands, Texas 77380 Re:Graf Acquisition Corp. IV Preliminary Proxy Statement on Schedule 14A Filed November 14, 2022 File No. 001-40427 Dear James A Graf: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Real Estate & Construction cc: Elliott M. Smith
Show Raw Text
United States securities and exchange commission logo
November 23, 2022
James A Graf
Chief Executive Officer
Graf Acquisition Corp. IV
1790 Hughes Landing Blvd., Suite 400
The Woodlands, Texas 77380
Re:Graf Acquisition Corp. IV
Preliminary Proxy Statement on Schedule 14A
Filed November 14, 2022
File No. 001-40427
Dear James A Graf:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc: Elliott M. Smith